Accurate preoperative staging of gastric cancer is of major importance for guiding therapeutic decision-making, preventing both under- and over-treatment. The purpose of this study is to investigate the diagnostic performance of the Multi-parametric magnetic resonance imaging (mpMRI) and dual-energy computed tomography (DECT) in gastric cancer.
Consecutive patients with preoperative pathologically confirmed GC by endoscopy and preoperative imaging data (DECT/mpMRI) were included.
No contraindications for CT/MRI examination
Written informed consent
Patients with a history of previous therapy.
Patients with recurrent gastric cancer
Patients with a history of severe allergy to contrast agents
Patients with imaging artefacts affect the evaluation
All patients diagnosed with gastric cancer by endoscopically biopsy will be considered for inclusion in the study.
Cohort
Prospective
DECT examination
Diagnostic testDECT examinations will be performed using a 192-slice CT scanner (SOMATOM, Force, Siemens, Forchheim, Germany).
mpMRI examination
Diagnostic testThe examinations were conducted on a 3-T MR scanner (MAGNETOM Skyra; Siemens Healthcare, Erlangen, Germany).
Diagnostic performance of DECT and mpMRI in tumor staging assessment
Accuracy for both imaging techniques in the prediction of tumor staging.
Diagnostic performance of DECT and mpMRI in tumor restaging assessment
Accuracy for both imaging techniques in the prediction of tumor restaging.
The kappa value
Inter-rater reliability of the DECT and mpMRI in tumor assessment
Predictive value of DECT and mpMRI after the neoadjuvant treatment for pathologic response
Pathological tumour regression grading (Mandard criterion): from 1 to 5 grading.
Disease free survival (DFS)
Survival analysis: Radiologic data predicting DFS.
Overall survival (OS)
Survival analysis: Radiologic data predicting OS.
Click on the lead sponsor to view all of their trials.
